{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-244725","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.525295+00:00","generated_at":"2026-06-29T12:56:23.340180+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tempest Therapeutics Q2 net loss $7.1M; cash $68.5M; appoints Ronit Simantov to board","bullets":["Closed merger and $30M PIPE in June 2021; cash position $68.5M vs $18.8M at Dec 2020; runway extends into Q1’23.","Net loss $7.1M ($7.63 per share) vs $5.2M ($11.42) in Q2 2020; six-month net loss $12.4M ($17.30).","TPST-1120 selected 600mg BID RP2D; observed deep confirmed partial response in combination with nivolumab in RCC.","Appointed Ronit Simantov, M.D. as Class III director effective Aug 6, 2021; granted option for 6,635 shares.","TREX-1 inhibitor advanced to picomolar IC50 potency; in vivo efficacy shown in mouse tumor model."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-244725","json":"https://secwatch.observer/filing/0001193125-21-244725.json","markdown":"https://secwatch.observer/filing/0001193125-21-244725.md","text":"https://secwatch.observer/filing/0001193125-21-244725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312521244725/0001193125-21-244725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312521244725/d186207d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T12:56:23.340180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31113f6221","claim":"Ronit Simantov was appointed as Class III director at Tempest Therapeutics, Inc..","evidence_excerpt":"Effective as of August 6, 2021, the Company’s Board of Directors (the “Board”) appointed Ronit Simantov, M.D. to serve as Class III director of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312521244725/0001193125-21-244725-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}